Legend Biotech Corp LEGN
Legend Biotech Corp (Nasdaq: LEGN) is an oncology drug developer. Its lead program, CARVYKTI (ciltacabtagene autoleucel, cilta-cel), is in Pre-clinical for relapsed/refractory multiple myeloma. Its next catalyst on record is CARVYKTI: Legend to present CITADEL study results on preemptive steroid strategy to mitigate immune effector cell-associated parkinsonism following CARVYKTI at ASH 2026. (December 2026).
Upcoming catalysts
- December 2026CARVYKTI — Legend to present CITADEL study results on preemptive steroid strategy to mitigate immune effector cell-associated parkinsonism following CARVYKTI at ASH 2026.
Findings showed a lower IEC-parkinsonism rate (1.6%) following CARVYKTI when a preemptive steroid strategy was implemented across four U.S. academic centers compared to historical data (2.9%).
- December 2026CARVYKTI — Legend to present CARTITUDE-4 subgroup analysis showing durable outcomes in patients with lenalidomide- and daratumumab-refractory multiple myeloma as early as second-line treatment at ASH 2026.
At 30 months after infusion, nearly 60% of patients were progression-free and median overall survival had not been reached.
- December 2026LB2501 — Legend to present updated data from first-in-human study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, at ASH 2026.
Updated findings from the first-in-human study of LB2501 (Poster #4169) showed overall and complete response rates of 100% among eight patients treated at dose level 2 (DL2), with response durations of up to five months as of the data cutoff.
- December 2026LUCAR-G39D — Legend to present follow-up findings from Phase 1 study of LUCAR-G39D, an investigational CD19/CD20 dual-targeting allogeneic CAR-T candidate, at ASH 2026.
Follow-up findings from the Phase 1 study of LUCAR-G39D (Poster #2392), an investigational CD19/CD20 dual-targeting allogeneic CAR-T candidate, will also be presented.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CARVYKTI (cilta-cel), co-developed/commercialized with Janssen | RRMM (4+ prior lines; 1+ prior line lenalidomide-refractory) | cell therapy | Approved |
| LB2501 (in vivo CD19/CD20 dual-targeting CAR-T) | relapsed/refractory B-cell non-Hodgkin lymphoma / B-cell malignancies | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Veracyte, Inc. VCYT
- Indaptus Therapeutics, Inc. INDP
- SL Science Holding Ltd SLBT
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
- Akari Therapeutics Plc AKTX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.